Assessing the Safety of Direct-Acting Antiviral Agents for Hepatitis C

IMPORTANCE: Recent reports based on the US Food and Drug Administration’s voluntary Adverse Events Reporting System raised questions about the safety of direct-acting antivirals (DAAs) for treatment of the hepatitis C virus (HCV). OBJECTIVE: To assess the rates of adverse events in patients with HCV...

Descripción completa

Detalles Bibliográficos
Autores principales: McGlynn, Elizabeth A., Adams, John L., Kramer, Jason, Sahota, Amandeep K., Silverberg, Michael J., Shenkman, Elizabeth, Nelson, David R.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Medical Association 2019
Materias:
Original Investigation
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6563580/
https://www.ncbi.nlm.nih.gov/pubmed/31173117
http://dx.doi.org/10.1001/jamanetworkopen.2019.4765

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6563580/
https://www.ncbi.nlm.nih.gov/pubmed/31173117
http://dx.doi.org/10.1001/jamanetworkopen.2019.4765

Ejemplares similares